Boardroom Alpha
Boardroom Alpha
CHRS · Additional Proxy Materials (DEFA14A) · Filed May 28, 2026

Coherus Oncology Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
May 28, 2026
Ticker
CHRS
Accession
0001104659-26-067154
Boardroom Alpha · Filing insights

Coherus adjourns the annual meeting to May 29 to vote on stock-option repricing; if approved, options are repriced and extended.

About Coherus Oncology Inc
Market cap
$235M
1Y TSR
+113.6%
3Y TSR
−28.7%
Board grade
C-
Sector
Healthcare
CEO
Dennis M Lanfear
Last annual meeting: May 27, 2026 · View full Coherus Oncology Inc profile →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant

Filed by a party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

 

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

 

Definitive Proxy Statement

 

 

Definitive Additional Materials

 

 

Soliciting Material under §240.14a-12

 

 

COHERUS ONCOLOGY, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

No fee required.

 

 

Fee paid previously with preliminary materials.

 

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.


SUPPLEMENT TO THE PROXY STATEMENT FOR THE

ANNUAL MEETING OF STOCKHOLDERS OF

COHERUS ONCOLOGY, INC.

HELD ON MAY 27, 2026

This supplement, dated May 27, 2026, amends and supplements the Proxy Statement of Coherus Oncology, Inc. (“we” or “Coherus”), dated April 20, 2026, as amended and supplemented to date (as amended and supplemented, the “Proxy Statement”), relating to the 2026 Annual Meeting of Stockholders (the “Annual Meeting”), with the following information.

Adjournment of Annual Meeting

On May 27, 2026, the Annual Meeting was convened with a quorum present. After completing the voting on Proposal Nos. 1, 2, 3, and 5, each as described in the Proxy Statement, we announced the adjournment of our Annual Meeting to ensure all votes have been counted regarding “Proposal No. 4 — Approval of the Reduction in the Exercise Price of Certain Outstanding Stock Options”, as described in the Proxy Statement. As noted in the Proxy Statement and pursuant to applicable law, Proposal No. 4 must be approved by the holders of the majority of the shares cast (excluding abstentions and broker non-votes). As announced at the Annual Meeting, the Annual Meeting was adjourned to reconvene on Friday, May 29, 2026 at 3:00 p.m., Pacific Time.

Impact of the Adjournment on the Repricing

In the event the stockholders approve Proposal No. 4 on May 29, 2026, the Eligible Options held (as defined in the Proxy Statement) by our Service Providers (as defined in the Proxy Statement) will automatically be repriced to the closing trading price per share of our common stock on May 29, 2026. In addition, the term of all Eligible Options will be extended for 10 years from May 29, 2026. However, except as otherwise determined by our board of directors or compensation committee, if any holder of an Eligible Option terminates service with the Company, or if a holder exercises his or her Eligible Option, in each case, prior to May 29, 2027, the exercise price of the holder’s Eligible Options will automatically increase to the original exercise price.

Important Information

Coherus has filed a definitive Proxy Statement with the Securities and Exchange Commission and has furnished to its stockholders a Proxy Statement in connection with the solicitation of proxies for the Annual Meeting. Coherus advises its stockholders to read the Proxy Statement relating to the Annual Meeting, as amended and supplemented, including as amended and supplemented by this supplement, because it contains important information.

Except as described in this supplement, none of the items or information presented in the Proxy Statement is affected by this supplement. This supplement does not provide all of the information that is important to your voting decisions at the Annual Meeting. The Proxy Statement contains other important additional information. We encourage you to carefully read this supplement together with the Proxy Statement.

If you have not already done so, please vote with respect to Proposal No. 4 by telephone, via the Internet, or by signing, dating and returning the proxy card or voting instruction card previously mailed to you. If you have already returned your proxy or voting instruction card or voted by telephone or via Internet with respect to Proposal No. 4, you do not need to take any action unless you wish to change your vote. No further votes will be solicited for the proposals approved at the Annual Meeting.


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Coherus Oncology Inc (CHRS)

Reference

Frequently asked questions

When did Coherus Oncology Inc file this DEFA14A?
Coherus Oncology Inc (CHRS) filed this Additional Proxy Materials (DEFA14A) with the SEC on May 28, 2026. The accession number assigned by EDGAR is 0001104659-26-067154.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Coherus adjourns the annual meeting to May 29 to vote on stock-option repricing; if approved, options are repriced and extended. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Coherus Oncology Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Coherus Oncology Inc has filed under CIK 1512762, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer